StockNews.com Begins Coverage on Titan Pharmaceuticals (NASDAQ:TTNP)

Equities research analysts at StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a research report issued on Sunday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Price Performance

Titan Pharmaceuticals stock opened at $3.20 on Friday. Titan Pharmaceuticals has a twelve month low of $3.03 and a twelve month high of $14.80. The company’s 50-day moving average price is $3.67 and its two-hundred day moving average price is $4.82.

Titan Pharmaceuticals (NASDAQ:TTNP) last released its quarterly earnings results on Friday, January 3rd. The specialty pharmaceutical company reported ($0.83) earnings per share for the quarter.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.